Compare Moderna, Inc. (MRNA) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Materials Select Sector SPDR Fund — how do they compare? Moderna, Inc. trades at $63.71 (market cap $24.18B), while Materials Select Sector SPDR Fund trades at $52.72. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | XLB | |
|---|---|---|
Market Cap | $24.18B | — |
Sector | Health | — |
52-Week High | $81.80 | $53.62 |
52-Week Low | $22.36 | $42.23 |
Enterprise Value | $20.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
XLB (Materials Select Sector SPDR ETF) trades at $52.68, down 0.94% on the day, while maintaining a bullish technical outlook with strong moving average support. The materials sector benefits from infrastructure spending and AI-related demand, though recent price action suggests some consolidation after the sector rebound. Technical indicators show mixed signals with overbought short-term RSI but strong trend momentum.
The ETF offers diversified exposure to materials companies with cyclical recovery potential, though valuation metrics appear limited after recent gains. Key risks include economic sensitivity and commodity price volatility, while positive earnings momentum and institutional interest provide support for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
